Bio Vitos Pharma (BIOVIT) Q4 2024 earnings summary

Executive summary

• 2024 marked the first full year as Bio Vitos Pharma, following the transformation from Hemcheck in 2023, with a focus on iron succinate products and IP rights for global markets.

• The company divested its legacy hemolysis detection business, freeing capital and streamlining operations.

• Leadership changes included the appointment of Sven Rohmann as interim CEO and a new board member, John Brauns.

• Nasdaq issued a delisting warning, which the company is contesting; the process is ongoing into 2025.

Financial highlights

• Net sales for 2024 were SEK 410,627, down from SEK 3,181,136 year-over-year.

• Operating loss for 2024 was SEK -17,975,866, compared to SEK -7,993,378 in 2023.

• Net loss for 2024 was SEK -19,863,840, an improvement from SEK -23,788,299 in 2023.

• Q4 2024 net sales were SEK 304,652, down from SEK 1,004,872 in Q4 2023.

• Earnings per share for 2024 were SEK -0.50, compared to SEK -0.81 in 2023 (adjusted for share consolidation).

Outlook and guidance

• The company aims to focus on commercializing its IP rights and advancing scientific studies, particularly for iron succinate.

• Management sees significant global market potential for its IP portfolio.